Skip to content
Peptigraph home

Tirzepatide vs Semaglutide: What the Research Shows

Tirzepatide and Semaglutide side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GLP-1 / GIP dual agonistFDA approved (Mounjaro, Zepbound)TirzepatideFDA-approved dual GIP and GLP-1 receptor agonist; in a large trial, mean weight change at week 72 was -15.0% on 5-mg and -19.5% on 10-mg weekly doses.[20]GLP-1 & metabolic+30% searchesGLP-1 agonistFDA approved (Ozempic, Wegovy, Rybelsus)SemaglutideFDA-approved GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus); in a 68-week trial in adults with obesity, mean weight change was -14.9% versus -2.4% with placebo.[21]GLP-1 & metabolic−38% searches
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Tirzepatide if…

  • you want an FDA-approved product: Zepbound (tirzepatide) is labelled, with diet and activity, for chronic weight management in adults with obesity or with overweight plus a weight-related condition[18]
  • you want the label that also covers obstructive sleep apnea: Zepbound is indicated for moderate to severe obstructive sleep apnea in adults with obesity[18]
  • you prioritise average weight loss in the one head-to-head trial: in SURMOUNT-5, mean weight change at week 72 was -20.2% with tirzepatide vs -13.7% with semaglutide[8]

Consider Semaglutide if…

  • you want an FDA-approved product: Wegovy (semaglutide) is labelled to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight plus a weight-related condition[19]
  • you want cardiovascular-outcomes data in obesity without diabetes: The primary cardiovascular composite occurred in 6.5% on semaglutide vs 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90).[22]
  • you want the label that includes liver disease: Wegovy has an accelerated-approval indication for MASH with moderate to advanced liver fibrosis in adults[19]
Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 8 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.

FieldTirzepatideSemaglutide
ClassGLP-1 / GIP dual agonistGLP-1 agonist
Also calledtirz, tirze, Mounjaro, Zepboundsema, Ozempic, Wegovy, Rybelsus, Wegovy pill
FDA statusFDA approved (Mounjaro, Zepbound)FDA approved (Ozempic, Wegovy, Rybelsus)
Half-lifeapproximately 5 dayssubcutaneous · FDA label (Mounjaro)approximately 1 weeksubcutaneous · FDA label (Ozempic)
Human studies we summarised24 human (22 randomized or controlled) of 30 summarised23 human (19 randomized or controlled) of 27 summarised
Typical study doses
Vial sizes sold5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
US searches per month1,220,000 · +30% searches368,000 · −38% searches

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

Tirzepatide and Semaglutide together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: 5 published studies included both (PMID 40353578, 34170647, 38976257, 41491349, 40886075). The FDA label names 2 drug interactions relevant to the pair.

Open the stack page
StackTirzepatide + Semaglutide, taken as separate injectionsStack page

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  7. 7Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  8. 8Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  9. 9These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
  11. 11Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  12. 12Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  13. 13PubMed search: (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.The New England journal of medicine · 2021PMID 34170647Accessed 2 Oct 2026
  15. 15Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.JAMA internal medicine · 2024PMID 38976257Accessed 2 Oct 2026
  16. 16Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).Diabetes, obesity & metabolism · 2026PMID 41491349Accessed 2 Oct 2026
  17. 17Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.JAMA · 2025PMID 40886075Accessed 2 Oct 2026
  18. 18ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  19. 19WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  20. 20Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
  21. 21Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
  22. 22Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.The New England journal of medicine · 2023PMID 37952131Accessed 2 Oct 2026

Found an error? Report a correction.